吉非替尼术前化疗对局限性非小细胞肺癌患者的作用研究  

Research on the Effects of Gefitinib on Localized NSCLC

作　　者：万金华[1] 张丽华[2] 张学钰[1] 范海银[1] 付洪帆[1] 易向军[1] 

机构地区：[1]江西省胸科医院,江西南昌3300062 [2]南昌市第一医院

出　　处：《中国医学创新》2013年第30期10-11,共2页Medical Innovation of China

摘　　要：目的:探讨吉非替尼术前辅助化疗对局限性非小细胞肺癌(NSCLC)患者的作用。方法:将96例局限性NSCLC患者分为观察组(52例)和对照组(44例),两组患者均给予择期手术治疗,观察组在术前给予250 mg/d吉非替尼辅助化疗,观察两组患者治疗疗效。结果:观察组术后局部复发率为3.85%(2/52)、远处转移率1.92%(1/52),明显低于对照组的11.36%(5/44)和6.82%(3/44),差异具有统计学意义(P<0.05);观察组患者术后1年生活质量优于对照组(P<0.05);两组患者1年生存率及术后并发症发生率比较无统计学意义(P>0.05)。结论:在NSCLC术前给予吉非替尼辅助化疗,可在降低复发及转移率的同时提高患者术后生活质量,对减轻患者痛苦、改善患者预后有积极意义。Objective： To investigate the effects of the preoperative adjuvant chemotherapy of gefitinib on the treatment of localized NSCLC. Method ： 96 cases localized NSCLC were divided into the observation group （ with 52 cases ） and the control group （ with 44 cases ） . Both groups were treated with selective operation. The observation group was treated with preoperative adjuvant chemotherapy of 250 mg/d gefitinib. Observations were carried out about the efficacy of both groups. Result： The post-operative local recurrence rate and the distant metastasis rate of the observation group were respectively 3.85% （ 2/52 ） and 1.92% （ 1/52 ）, significantly lower than 11.36% （ 5/44 ） and 6.82% （ 3/44 ） of the control group （ P〈0.05 ） . The life quality of the observation group one year after the operation was better than that of the control group （ P〈0.05 ） . There was no statistic significance in the comparison of both groups＇ one-year production rate and occurrence rate of post-operative complications （ P〉0.05 ） . Conclnsion： Applying preoperative adjuvant chemotherapy of gefitinib on the treatment of localized NSCLC can reduce the recurrence rate and the transport rate and improve patients＇ postoperative life quality, as well as imposing positive effects on alleviating patients＇ pain and improve their prognosis.

关 键 词：局限性非小细胞肺癌 吉非替尼 复发率 转移率 

分 类 号：R734.2[医药卫生—肿瘤]